In a Phase II trial, 23 percent of patients achieved complete remission plus complete remission with partial hematologic recovery on Revuforj.

A man with neurofibromas who didn't know he's been clinically diagnosed with NF1, learns he harbors a deeply intronic, likely ...

AGC Biologics will help the company develop and manufacture RDP-101 in line with FDA standards and for the commercial market.

The payment was triggered because Kura dosed the first AML patient in a Phase III trial of the menin inhibitor.

In the study, researchers molecularly screened nearly 2,000 cancer patients and matched 14 percent into a study arm.

In the small first-in-human study, AB-1002 showed an encouraging safety profile and early signs of efficacy, investigators ...

Approved KRAS inhibitors Lumakras and Krazati may soon face more competition as second-generation G12C inhibitors and other KRAS approaches advance.

Amid steady Q3 growth, Roche's giredestrant-Afinitor combo extended survival in advanced ER-positive, HER2-negative early breast cancer.

The firm also said this week it will conduct a pivotal study next year of its PRMT5 inhibitor in MTAP-deleted pancreatic cancer.

The firm's monoclonal antibody latozinemab did not slow disease progression in patients with dementia due to progranulin gene mutations.

NEW YORK – BioNTech said Wednesday that it began an exchange offer to complete its $1.25B all-stock acquisition of mRNA immunotherapy developer CureVac in a deal that was announced in June.